The Application of anti-vascular endothelial growth factor therapy in ophthalmology

doi:10.3877/cma.j.issn.2095-2007.2017.02.001

Abstract

Abstract:

It has been more than ten years since anti-vascular endothelial growth factor drugs (anti-VEGF) were officially listed and used in clinic, up to now. During these years, the effects of anti-VEGF drugs have been recognized by eye care professionals, and these drugs have propelled the development of ophthalmology and the related health care industry. This article reviews the development course of anti-VEGF drugs, and anti-VEGF drugs for the treatment of various diseases of the eye are summarized, and the actual cases picture to show the efficacy of anti-VEGF drugs.

Key words: Anti-vascular endothelial growth factor, Ophthalmology, Application

Huijun Qi. The Application of anti-vascular endothelial growth factor therapy in ophthalmology[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2017, 07(02): 49-59.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhykyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2007.2017.02.001

https://zhykyxzz.cma-cmc.com.cn/EN/Y2017/V07/I02/49

Figures/Tables 8

References 85

[1]	Nguyen QD, Brown DM, Marcus DM, et a1. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE[J]. Ophthalmology, 2012, 119(4):789-801.
[2]	Nguyen QD, Shah SM, Heier JS, et a1. Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in diabetes (READ－2) study[J]. Ophthalmology, 2009, 116(11):2175-2181.
[3]	Rofagha S, Bhisitkul RB, Boyer DS, et a1. Seven－year outcomes in ranibizumab－treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN－UP)[J]. Ophthalmology, 2013, 120(11):2292-2299.
[4]	Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age－related macular degeneration[J]. N Engl J Med, 2006, 355(14):1432-1444.
[5]	Thach AB, Yau L, Hoang C, et a1. Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials[J]. Ophthalmology, 2014, 121(5):1059-1066.
[6]	闫瑾，刘美欣．抗VEGF药物治疗眼部新生血管性疾病[J]．中国实用眼科杂志，2014,32(2):97-100.
[7]	Ventrice P, Leporini C, Aloe JF, et al. Anti－vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases[J]. J Pharmacol pharmacother, 2013, 4(Suppl. 1):38-42.
[8]	周洪伟，吴强．血管内皮生长因子及其受体与眼底新生血管[J]．国际眼科杂志，2007,7(3):791-795.
[9]	李灵，席新华．Avastin在眼科中的应用[J]．国际眼科杂志，2008,8(3):582-583.
[10]	姜浩，赵堪兴．玻璃体内注射bevacizumab治疗糖尿病视网膜病变[J]．中华实验眼科杂志，2009,27(4):349-352.
[11]	冯斐，赵培泉．Avastin在眼科的应用研究进展[J]．眼科新进展，2009,29(3):231-233.
[12]	于同利，毕宏生．Avastin在眼科应用的研究进展[J]．国际眼科杂志，2008,8(4):810-812.
[13]	Maturi RK, Bleau LA, Wilson DL. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment[J]. Retina, 2006, 26(3):270-274.
[14]	Ruiz－Moreno JM, Montero JA, Gomez－Ulla F, et al. Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1－year outcome[J]. Br J Ophthalmol, 2009, 93(4):448-451.
[15]	周丽琼，袁援生．Avastin眼内用药的安全性评价[J]．医学综述，2010,16(10):1551-1553.
[16]	张军燕，马凯．抗血管内皮生长因子药物辅助治疗眼内新生血管性疾病的现状与展望[J/CD]．中华眼科医学杂志(电子版)，2013,3(2):67-73.
[17]	杜宇翔，郭大东，司俊康，等．贝伐单抗和雷珠单抗治疗渗出型老年性黄斑变性有效性Meta分析[J]．中华眼底病杂志，2014,30(3):304-307.
[18]	雷春燕．眼科新一代抗血管内皮生长因子药物的基础研究及临床试验进展[J]．中华实验眼科杂志，2014,32(10):938-942.
[19]	刘姝林，陈有信．抗VEGF药物治疗视网膜中央静脉阻塞并发黄斑水肿的Meta分析[J]．中华实验眼科杂志，2014,32(1):56-61.
[20]	Parmeggiani F, Sorrentino FS, Romano MR, et a1. Mechanism of inflammation in age－related macular degeneration: an up－to－date on genetic landmarks[J]. Mediators Inflamm, 2013, 2013:e435707.
[21]	Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age－related macular degeneration: two－year results of the ANCHOR study[J]. Ophthalmology, 2009, 116(1):57-65.
[22]	Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab versus verteporfin for neovascular age－related macular degeneration[J]. N Engl J Med, 2006, 335(14):1432-1444.
[23]	Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable－dosing regimen with intravitreal ranibizumab for neovascular age－related macular degeneration: year 2 of the PrONTO study[J]. Am J Ophthalmol, 2009, 148(1):43-58.
[24]	MartinDF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age－related macular degeneration: two－year results[J]. Ophthalmology, 2012, 119(7):1388-1398.
[25]	Muniraju R, Ramu J, Sivaprasad S. Three－year visual outcome and injection frequency of intravitreal ranibizumab therapy for neovascular age－related macular degeneration[J]. Ophthamologica, 2013, 230(1):27-33.
[26]	Holz FG, Amoaku W, Donate J, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age－related macular degeneration: the SUSTAIN study[J]. Ophthalmology, 2011, 118(4):663-671.
[27]	Arias L, Roman I, Masuet－Aumatell C, et al. One－year results of a flexible regimen with ranibizumab therapy in macular degeneration: relationship with the number of injections[J]. Retina, 2011, 31(7):1261-1267.
[28]	Bandukwala T, Muni RH, Schwartz C, et al. Effectiveness of intravitreal ranibizumab for the treatment of neovascular age－related macular degeneration in a Canadian retina practice: a retrospective review[J]. Can J Ophthalmol, 2010, 45(6):590-595.
[29]	Hjelmqvist L, Lindberg C, Kanulf P, et al. One－year outcomes using ranibizumab for neovascular age－related macular degeneration: results of a prospective and retrospective observational multicentre study[J]. J Ophthalmol, 2011, 2011:e405724.
[30]	Kumar A, Sahni JN, Stangos AN, et al. Effectiveness of ranibizumab for neovascular age－related macular degeneration using clinician－determined retreatment strategy[J]. Br J Ophthalmol, 2011, 95(4):530-533.
[31]	Williams TA, Blyth CP. Outcome of ranibizumab treatment in neovascular age related macular degeneration in eyes with baseline visual acuity better than 6/12[J]. Eye (Lond), 2011, 25(12):1617-1621.
[32]	Qi HJ, Li XX, Zhang JY, et al. Efficacy and safety of ranibizumab for wet age－related macular degeneration in Chinese patients[J]. Int J Ophthalmol, 2017, 10(1):91-97.
[33]	Schmidt－Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age－related macular degeneration: ninety－six－week results of the VIEW studies[J]. Ophthalmology, 2014, 121(1):193-201.
[34]	Li X, Xu G, Wang Y, et al. Safety and efficacy of conbercept in neovascular age－related macular degeneration: results from a 12－month randomized phase 2 study: AURORA study[J]. Ophthalmology, 2014, 121(9):1740-1747.
[35]	中华医学会眼科学分会眼底病学组中国老年性黄斑变性临床指南与临床路径制订委员会．中国老年性黄斑变性临床诊断治疗路径[J]．中华眼底病杂志，2013,29(4):343-355.
[36]	Yannuzzi LA, Sorenson J, Spaide RF, at al. Idiopathic polypoidal choroidal vasculopathy (IPCV)[J]. Retina, 1990, 10(1):1-8.
[37]	Wong RL, Lai TY. Polypoidal choroidal vasculopathy: an update on therapeutic approaches[J]. J Ophthalmic Vis Res, 2013, 8(4):359-371.
[38]	Ciardella AP, Donsoff IM, Huang SJ, et al. Polypoidal choroidal vasculopathy[J]. Surv Ophthalmol, 2004, 49(1):25-37.
[39]	Gomi F, Tano Y. Polypoidal choroidal vasculopathy and treatments[J]. Curr Opin Ophthalmol, 2008, 19(3):208-212.
[40]	Laude A, Cackett PD, Vithana EN, et al. Polypoidal choroidal vasculopathy and neovascular age－related macular degeneration: same or different disease[J]. Prog Retin Eye Res, 2010, 29(1):19-29.
[41]	Huang L, Zhang H, Cheng CY, et al. A missense variant in FGD6 confers increased risk of polypoidal choroidal vasculopathy[J]. Nat Genet, 2016, 48(6):640-647.
[42]	Uyama M, Wada M, Nagai Y, et al. Polypoidal choroidal vasculopathy: natural history[J]. Am J Ophthalmol, 2002, 133(5):639-648.
[43]	Otani A, Sasahara M, Yodoi Y, et al. Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy[J]. Am J Ophthalmol, 2007, 144(1):7-14.
[44]	Lee WK, Lee PY, Lee SK. Photodynamic therapy for polypoidal choroidal vasculopathy: vaso－occlusive effect on the branching vascular network and origin of recurrence[J]. Jpn J Ophthalmol, 2008, 52(2):108-115.
[45]	Mori R, Yuzawa M, Lee Z, et al. Factors influencing visual outcome of polypoidal choroidal vasculopathy one year after photodynamic therapy[J]. Graefes Arch Clin Exp Ophthalmol, 2010, 248(9):1233-1239.
[46]	Tsuchiya D, Yamamoto T, Kawasaki R, et al. Two－year visual outcomes after photodynamic therapy in age－related macular degeneration patients with or without polypoidal choroidal vasculopathy lesions[J]. Retina, 2009, 29(7):960-965.
[47]	Kang HM, Kim YM, Koh HJ. Five－year follow－up results of photodynamic therapy for polypoidal choroidal vasculopathy[J]. Am J Ophthalmol, 2013, 155(3):438-447.
[48]	Hirami Y, Tsujikawa A, Otani A, et al. Hemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathy[J]. Retina, 2007, 27(3):335-341.
[49]	Musashi K, Tsujikawa A, Hirami Y, et al. Microrips of the retinal pigment epithelium in polypoidal choroidal vasculopathy[J]. Am J Ophthalmol, 2007, 143(5):883-885.
[50]	Koh AH, Panel EP, Chen LJ, et al. Polypoidal choroidal vasculopathy: evidence－based guidelines for clinical diagnosis and treatment[J]. Retina, 2013, 33(4):686-716.
[51]	Gomi F, Oshima Y, Mori R, et al. Initial versus delayed photodynamic therapy in combination with ranibizumab for treatment of polypoidal choroidal vasculopathy: The Fujisan Study[J]. Retina, 2015, 35(8):1569-1576.
[52]	Koh A, Lee WK, Chen LJ, et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy[J]. Retina, 2012, 32(8):1453-1464.
[53]	Oishi A, Kojima H, Mandai M, et al. Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12－month LAPTOP study results[J]. Am J Ophthalmol, 2013, 156(4):644-651.
[54]	Balaratnasingam C, Lee WK, Koizumi H, et al. Polypoidal Choroidal Vasculopathy: A Distinct Disease or Manifestation of Many[J]. Retina, 2016, 36(1):1-8.
[55]	Tong JP, Chan WM, Liu DT, et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium－derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization[J]. Am J Ophthalmol, 2006, 141(3):456-462.
[56]	Matsuoka M, Ogata N, Otsuji T, et al. Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy[J]. Br J Ophthalmol, 2004, 88(6):809-815.
[57]	Lai TY, Chan WM, Liu DT, et al. Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy[J]. Br J Ophthalmol, 2008, 92(5):661-666.
[58]	Hikichi T, Higuchi M, Matsushita T, et al. Results of 2 years of treatment with as－needed ranibizumab reinjection for polypoidal choroidal vasculopathy[J]. Br J Ophthalmol, 2013, 97(5):617-621.
[59]	Miura M, Iwasaki T, Goto H. Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis[J]. Clin Ophthalmol, 2013, 7:1591-1595.
[60]	Ijiri S, Sugiyama K. Short－term efficacy of intravitreal aflibercept for patients with treatment－naïve polypoidal choroidal vasculopathy[J]. Graefes Arch Clin Exp Ophthalmol, 2015, 253(3):351-357.
[61]	Qu J, Cheng Y, Li X, et al. Efficacy of intravitreal injection of conbercept in polypoidal choroidal vasculopathy: Subgroup Analysis of the Aurora Study[J]. Retina, 2016, 36(5):926-937.
[62]	中华医学会眼科学会眼底病学组．我国糖尿病视网膜病变临床诊疗指南(2014年)[J]．中华眼科杂志，2014,50(11),851-863.
[63]	Mitchell P, Wong TY, Diabetic Macular Edema Treatment Guideline Working Group. Management paradigms for diabetic macular edema[J]. Am J Ophthalmol, 2014, 157(3):505-513.
[64]	Martin DF, Maguire MG. Treatment choice for diabetic macular edema[J]. N Engl J Med, 2015, 372(13):1260-1261.
[65]	Olsen TW. Anti－VEGF Pharmacotherapy as an Alternative to Panretinal Laser Photocoagulation for Proliferative Diabetic Retinopathy[J]. JAMA, 2015, 314(20):2135-2136.
[66]	Patz A, Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion[J]. Am J Ophthalmol, 1984, 98(3):374-375.
[67]	Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12－month outcomes of a phase III study[J]. Ophthalmology, 2011, 118(8):1594-1602.
[68]	Campochiaro PA, Clark WL, Boyer DS, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24－week results of the VIBRANT study[J]. Ophthalmology, 2015, 122(3):538-544.
[69]	Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six－month primary end point results of a phase III study[J]. Ophthalmology, 2010, 117(6):1124-1133.
[70]	Scott IU, Ip MS, Van Veldhuisen PC, et al. A randomised trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6[J]. Arch Ophthalmol, 2009, 127(9):1115-1128.
[71]	Haller JA, Bandello F, Belfort R, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve－month study results[J]. Ophthalmology, 2011, 118(12):2453-2460.
[72]	Spaide RF. Choroidal neovascularization in younger patients[J]. Curr Opin Ophthalmol, 1999, 10(3):177-181.
[73]	Lindblom B, Andersson T. The prognosis of idiopathic choroidal neovascularization in persons younger than 50 years of age[J]. Ophthalmology, 1998, 105(10):1816-1820.
[74]	Flaxel CJ. The use of systemic steroids and photodynamic treatment for choroidal neovascularisation in young patients[J]. Br J Ophthalmol, 2007, 91(5):564-565.
[75]	Mandal S, Garg S, Venkatesh P, et al. Intravitreal bevacizumab for subfoveal idiopathic choroidal neovascularization[J]. Arch Ophthalmol, 2007, 125(11):1487-1492.
[76]	Kang HM, Koh HJ. Intravitreal anti－vascular endothelial growth factor therapy versus photodynamic therapy for idiopathic choroidal neovascularization[J]. Am J Ophthalmol, 2013, 155(4):713-719.
[77]	Qi HJ, Li XX, Tao Y. Outcome of intravitreal bevacizumab for idiopathic choroidal neovascularization in a Chinese population[J]. Can J Ophthalmol, 2010, 45(4):381-385.
[78]	袁建树，吴越，王育文．病理性近视脉络膜新生血管抗VEGF治疗期间黄斑中心凹下的脉络膜厚度变化[J]．国际眼科杂志，2016,16(5):905-908.
[79]	Vadala M, Pece A, Cipolla S, et al. Is ranibizumab effective in stopping the loss of vision for choroidal neovascularisation in pathologic myopia? A long－term follow－up study[J]. Br J Ophthalmol, 2011, 95(5):657-661.
[80]	欧阳丽娟，皮练鸿．早产儿视网膜病变治疗研究进展[J]．激光杂志，2015,36(2):135-138.
[81]	范雅文，项道满，陈锋，等．早产儿视网膜病变激光光凝与玻璃体腔注射Bevacizumab对比研究[J]．中华实用眼科杂志，2014,32(12):1444-1448.
[82]	Budning AS, Heon E, Gallie BL. Visual prognosis of Coats′ disease[J]. J AAPOS, 1998, 2(6):356-359.
[83]	Schefler AC, Berrocal AM, Murray TG. Advanced Coats′ disease. Management with repetitive aggressive laser ablation therapy[J]. Retina, 2008, 28(Suppl. 3):38-41.
[84]	Ozdamar Y, Berker N, Batman C, et al. Vitreoretinal surgery in advanced coats disease [J]. Retin Cases Brief Rep, 2009, 3(1):57-59.
[85]	Sun Y, Jain A, Moshfeghi DM. Elevated vascular endothelial growth factor levels in Coats disease: rapid response to pegaptanib sodium[J]. Graefes Arch Clin Exp Ophthalmol[J]. 2007, 245(9):1387-1388.

Please choose a citation manager

Content to export